Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0386)
| Name |
Lycium barbarumpolysaccharide
|
||||
|---|---|---|---|---|---|
| Drug Type |
Small molecule
|
||||
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Suppressor | |||
| Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
| Pathway Response | Ferroptosis | hsa04216 | ||
| Cell Process | Cell ferroptosis | |||
| Cell proliferation | ||||
| In Vitro Model | MCF-7 cells | Breast carcinoma | Homo sapiens | CVCL_0031 |
| MDA-MB-231 cells | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
| Response regulation | Lycium barbarum polysaccharide (LBP) effectively inhibited proliferation of breast cancer cells and promoted ferroptosis by modulation of the xCT/GPX4 pathway. GPX4 inactivity and repression of SLC7A11 (the gene for xCT) result in ROS accumulation, thereby modulating ferroptosis. | |||